Affordable Access

deepdyve-link
Publisher Website

Reverse Translational Research of ABCG2 (BCRP) in Human Disease and Drug Response.

Authors
  • Brackman, Deanna J1
  • Giacomini, Kathleen M1, 2
  • 1 Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
  • 2 Institute of Human Genetics, University of California San Francisco, San Francisco, California, USA.
Type
Published Article
Journal
Clinical Pharmacology & Therapeutics
Publisher
Wiley (Blackwell Publishing)
Publication Date
Feb 01, 2018
Volume
103
Issue
2
Pages
233–242
Identifiers
DOI: 10.1002/cpt.903
PMID: 29023674
Source
Medline
Language
English
License
Unknown

Abstract

Reverse translational research takes a bedside-to-bench approach, using sophisticated basic research to explain the biological mechanisms behind observed clinical data. For transporters, which play a role in human disease and drug response, this approach offers a distinct advantage over the typical translational research, which often falters due to inadequate in vitro and preclinical animal models. Research on ABCG2, which encodes the Breast Cancer Resistance Protein, has benefited immensely from a reverse translational approach due to its broad implications for disease susceptibility and both therapeutic and adverse drug response. In this review, we describe the success of reverse translational research for ABCG2 and opportunities for further studies. © 2017 American Society for Clinical Pharmacology and Therapeutics.

Report this publication

Statistics

Seen <100 times